CN115485294A - T细胞受体 - Google Patents

T细胞受体 Download PDF

Info

Publication number
CN115485294A
CN115485294A CN202180032592.3A CN202180032592A CN115485294A CN 115485294 A CN115485294 A CN 115485294A CN 202180032592 A CN202180032592 A CN 202180032592A CN 115485294 A CN115485294 A CN 115485294A
Authority
CN
China
Prior art keywords
tcr
amino acid
chain
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180032592.3A
Other languages
English (en)
Chinese (zh)
Inventor
贾斯迪普·曼恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
2 Savinti Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 2 Savinti Biology filed Critical 2 Savinti Biology
Publication of CN115485294A publication Critical patent/CN115485294A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180032592.3A 2020-03-27 2021-03-26 T细胞受体 Pending CN115485294A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000800P 2020-03-27 2020-03-27
US63/000,800 2020-03-27
PCT/US2021/024370 WO2021195503A1 (en) 2020-03-27 2021-03-26 T cell receptors

Publications (1)

Publication Number Publication Date
CN115485294A true CN115485294A (zh) 2022-12-16

Family

ID=77890524

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180032592.3A Pending CN115485294A (zh) 2020-03-27 2021-03-26 T细胞受体

Country Status (11)

Country Link
US (1) US20230124640A1 (https=)
EP (1) EP4126924A4 (https=)
JP (2) JP7738007B2 (https=)
KR (1) KR20220160040A (https=)
CN (1) CN115485294A (https=)
AU (1) AU2021244594A1 (https=)
BR (1) BR112022019380A2 (https=)
CA (1) CA3177181A1 (https=)
IL (1) IL296827A (https=)
MX (1) MX2022012062A (https=)
WO (1) WO2021195503A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003855A (zh) * 2023-09-20 2023-11-07 广州市老人院 一种t细胞受体及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102795A2 (en) * 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
WO2019070541A1 (en) * 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
CN114375301A (zh) * 2019-05-08 2022-04-19 基因医疗免疫疗法有限责任公司 工程改造的t细胞

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361794B2 (en) * 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
LT3424947T (lt) * 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
CN102876715B (zh) 2012-09-05 2014-07-23 南方医科大学 一种用于结核/hiv共感染基因治疗的逆转录病毒载体及其应用
CN102911267B (zh) 2012-09-19 2014-04-02 南方医科大学 一种结核/hiv抗原肽双特异性tcr、其重组逆转录病毒载体与应用
EP3472208B9 (en) 2016-06-17 2023-10-04 Medigene Immunotherapies GmbH T cell receptors and uses thereof
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CA3225252A1 (en) * 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102795A2 (en) * 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
WO2019070541A1 (en) * 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
CN114375301A (zh) * 2019-05-08 2022-04-19 基因医疗免疫疗法有限责任公司 工程改造的t细胞

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003855A (zh) * 2023-09-20 2023-11-07 广州市老人院 一种t细胞受体及其应用
CN117003855B (zh) * 2023-09-20 2024-02-23 广州市老人院 一种t细胞受体及其应用

Also Published As

Publication number Publication date
KR20220160040A (ko) 2022-12-05
IL296827A (en) 2022-11-01
CA3177181A1 (en) 2021-09-30
BR112022019380A2 (pt) 2022-11-29
JP2025172113A (ja) 2025-11-20
EP4126924A1 (en) 2023-02-08
EP4126924A4 (en) 2024-04-24
JP7738007B2 (ja) 2025-09-11
JP2023519868A (ja) 2023-05-15
AU2021244594A1 (en) 2022-12-01
US20230124640A1 (en) 2023-04-20
MX2022012062A (es) 2023-01-11
WO2021195503A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
CN114375301B (zh) 工程改造的t细胞
JP2025172113A (ja) Ｔ細胞受容体
JP7431735B2 (ja) Ｄａｒｉｃインターロイキン受容体
US20240342215A1 (en) Engineered t cell receptors fused to binding domains from antibodies
CN114206928B (zh) Cd33靶向免疫疗法
KR20230053650A (ko) Bcma 키메라 항원 수용체
EP3966249A1 (en) Cll-1 targeted immunotherapies
CN115397864A (zh) 经修饰的ccr多肽和其用途
EP3966338A1 (en) Cd123 targeted immunotherapies
EA052725B1 (ru) Т-клеточные рецепторы
WO2022099176A1 (en) Aml targeted immunotherapies
EA049270B1 (ru) Сконструированные т-клетки

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250421

Address after: USA New York

Applicant after: REGENERON PHARMACEUTICALS, Inc.

Country or region after: U.S.A.

Address before: Massachusetts, USA

Applicant before: 2 savinti biology

Country or region before: U.S.A.